#USA #California #oncology #Gilead #Kite

Gilead and Kite Present New Oncology Data at 2026 ASCO and EHA

Gilead Sciences, headquartered in Foster City, California, alongside Kite, their subsidiary based in Santa Monica, California, has announced a significant agenda for the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, set to take place from May 29 to June 2, and the 2026 European Hematology Association (EHA) Annual Meeting scheduled for June 11 to 14. They will present over 25 abstracts, including six oral presentations, showcasing groundbreaking data related to antibody-drug conjugates (ADCs) and cell therapies in oncological settings, aimed at advancing treatment options for patients with various forms of cancer, including metastatic triple-negative breast cancer (mTNBC) and relapsed/refractory multiple myeloma.

The focus of the presentations indicates the growing scientific evidence underlying Gilead's diverse oncology portfolio and pipeline, reinforcing the company's leadership in innovative cancer therapies. Aiming to highlight the potential introduction of novel therapies, they will unveil data analyses for Trodelvy (sacituzumab govitecan) in mTNBC treatment and for anitocabtagene autoleucel (anito-cel), which is currently under development for relapsed/refractory (RR) multiple myeloma.

Dr. Dietmar Berger, Gilead’s Chief Medical Officer, indicated that the latest findings will showcase critical growth points for Gilead’s oncology portfolio, evolving alongside a rapidly maturing pipeline and late-stage clinical trials. He emphasized, "The data we present at ASCO and EHA will serve to elucidate our trajectory in ADCs and cell therapies, further strengthening our commitment to meaningful advancements for patients living with cancer."

Key Highlights from ASCO Presentations

1. Trodelvy and Keytruda in mTNBC: Gilead will share new analyses from the ASCENT-04 and ASCENT-03 trials, which aim to define the clinical profile of Trodelvy in combination with Keytruda (pembrolizumab) as a first-line treatment for mTNBC. This includes evaluations of progression-free survival (PFS2) leading to secondary treatments, noted by abstract numbers #LBA1000 and #1001.

2. Anito-cel Manufacturing Results: Kite will present preliminary manufacturing results from the iMMagine-3 trial and GEM-AnitoFIRST study, highlighting the consistency and operational feasibility of anito-cel in treating patients with RR or newly diagnosed multiple myeloma, supporting broader clinical development (Abstract number #2550).

3. CAR T-cell Therapy for Recurrent Glioblastoma: A phase I trial investigating CAR T-cell therapy for recurrent glioblastoma will be presented by researchers from the University of Pennsylvania, shedding light on continued advancements in solid tumor cell therapy (Abstract# 2013).

Key Highlights from EHA Presentations

• - KITE-753 Phase I Trial: Results from the KITE-753 phase I trial aimed at evaluating Kite’s enhanced DuoCore™ CAR T-cell therapy for patients with relapsed/refractory B-cell lymphoma, showing promising safety and efficacy data, will be revealed (Abstract number #4208619).

The abstracts selected for the 2026 ASCO annual meeting are freely available on the ASCO website, demonstrating Gilead and Kite's ongoing commitment to pushing the boundaries of oncology treatment through innovative therapies. With continued emphasis on real-world evidence and manufacturing capabilities, both companies are set to show a significant trajectory in their operations and research conclusions, promising changes for patients in need of new treatment perspectives.

Conclusion

As Gilead and Kite prepare to share their findings, the future looks optimistic for oncology patients benefiting from advancements in antibody-drug conjugates and CAR T-cell therapies. The dedication to clinical excellence underscores a significant commitment to improving patient lives amidst the challenges posed by cancer treatment.